Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer Authors: Jingxia Zhang, Weiyan Shan, Jie Yu, Huan Shi, Qiaoping Xu, Hongkai Shang Published: 2026 ABSTRACT ABSTRACTOvarian cancer (OC) remains a lethal gynecological malignancy with challenges in early diagnosis, treatment monitoring, and overcoming drug resistance. Liquid biopsy, a noninvasive approach analyzing tumor‐derived components in bodily fluids, has emerged as a promising tool in OC management. This review summarizes advances in liquid biopsy technologies, focusing on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). ctDNA enables minimally invasive assessment for diagnosis, prognosis, treatment guidance (e.g., BRCA1/2‐targeted therapy), minimal residual disease (MRD) detection, and monitoring of tumor evolution. CTCs, particularly clusters, provide insights into metastasis and therapeutic response. Emerging modalities such as tumor‐educated platelets (TEPs), circular RNAs (circRNAs), and exosomes and protease activity‐based liquid biopsy also show diagnostic and prognostic potential. Despite technical challenges like standardization and sensitivity, liquid biopsy holds significant promise for personalized OC care, with ongoing efforts to translate these technologies into clinical practice. Introduction Ovarian cancer (OC), a malignant tumor originating from ovarian tissue, represents the most lethal gynecological malignancy [1]. Worldwide, global statistics from 2022 reported 324,603 new cases and 206,956 deaths, with Asia bearing the highest burden (49.2% of incident cases and 56.1% of mortality worldwide) [2]. Projected data indicate that the United States will have 20,890 new OC cases and 12,730 OC‐related deaths in 2025 [3]. Histologically, OC is primarily classified into epithelial tumors, sex cord‐stromal tumors, and germ cell tumors, with epithelial ovarian cancer (EOC) accounting for 95% of malignant cases [4]—one of the most challenging and lethal types in gynecological oncology. The World Health Organization (WHO) further categorizes EOC into five major subtypes based on epithelial morphology: high‐grade serous carcinoma (HGSC, 70%), endometrioid carcinoma (EC, 10%), clear cell carcinoma (CCC,10%), mucinous carcinoma (MC, 3%), and low‐grade serous carcinoma (LGSC, 3%) [5]. Although 90% of OC patients can be cured if detected early [6], the disease remains difficult to diagnose at an early stage due to nonspecific initial symptoms (e.g., abdominal distension, pain) that mimic gastrointestinal disorders. Consequently, approximately 80% of patients present with metastatic disease at the time of diagnosis [7], a key factor contributing to its high mortality rate. According to the National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2024), OC management encompasses a multi‐modal therapeutic arsenal. Current standard‐of‐care options include cytoreductive surgery, platinum‐based combination chemotherapy with paclitaxel, hyperthermic intraperitoneal chemotherapy (HIPEC), targeted therapy with bevacizumab, and PARP inhibitors. Emerging immunotherapeutic agents are still under clinical evaluation and have not been established as standard of care. Notably, while many patients demonstrate favorable initial responses to treatment, the majority of advanced OC cases relapse within years, with the underlying cause lying in the development of acquired drug resistance to chemotherapy and targeted agents [8]. Intrinsic resistance, defined as the inherent ability of cancer cells to withstand initial therapy, typically leads directly to primary treatment failure and early tumor relapse. In contrast, acquired resistance, which develops gradually via genetic or epigenetic alterations under therapeutic pressure, is closely associated with late tumor recurrence [9]. These two resistance mechanisms together constitute another pivotal factor driving the disease's high recurrence and mortality rate [10, 11]. Thus, early diagnosis and treatment monitoring represent critical strategies to reduce OC mortality. In this context, liquid biopsy, an emerging molecular analytical approach in oncology, offers a novel paradigm for OC management. Broadly defined, “liquid biopsy” refers to the sampling and analysis of various biological fluids‐predominantly blood, but also urine, ascites, or pleural effusion—for tumor‐derived components [12]. By identifying and analyzing DNA fragments released from tumor cells or apoptotic tumor cells into the bloodstream, liquid biopsy provides detailed insights into tumor characteristics, including progression, staging, heterogeneity, genetic mutations, and clonal evolution [13, 14]. This technology not only demonstrates substantial potential in early tumor screening and targeted therapy but also serves as a pivotal tool for detecting MRD, predicting recurrence, and capturing real‐time drug resistance—thereby enabling early disease monitoring and personalized treatment optimization [15]. Key biomarkers analyzed via liquid biopsy include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular RNA (e.g., microRNA), and extracellular vesicles [16]. Among these, ctDNA and CTCs are regarded as the two primary components of liquid biopsy [17], forming the focus of this review. Notably, protease activity‐based liquid biopsy serves as a functional complement: it reflects tumor invasive potential by detecting the aberrant activation of tumor‐associated proteases, which differentiates it from conventional tumor burden‐related biomarkers such as ctDNA and CA‐125. Here, we summarize the clinical applications of liquid biopsy in OC, encompassing early diagnosis, prognostic evaluation, recurrence detection, treatment response monitoring, and recent technological advancements. Traditional Screening and Diagnosis of Ovarian Cancer In accordance with the position of authoritative bodies including the British Gynaecological Cancer Society (BGCS) [18], there is currently no fully validated, mature OC screening strategy suitable for asymptomatic general populations [19]. The most common methods studied for OC screening are transvaginal ultrasonography, bimanual palpation, and measurement of the serum tumor marker CA‐125 [19]. Among them, CA‐125 is recognized as an optimal and widely utilized biomarker for the early clinical detection of OC. Nevertheless, it has a low predictive value (5%) and lacks specificity and sensitivity. A meta‐analysis conducted by Ferraro et al. [20] reported a specificity of 78% for CA‐125 in detecting OC. Only 50% of early‐stage patients have elevated CA‐125 levels, resulting in a relatively low sensitivity (50%–62%) for the detection of early‐stage OC. Moreover, CA‐125 levels may increase in other diseases, such as endometriosis, breast cancer, and lung cancer [21]. In the PLCO trial, the positive predictive value (PPV) of CA‐125 (> 35 U/mL) was determined to be 2.6% [22]. TVS is utilized to examine the structures of the adnexa and uterus. Although it provides some utility in the diagnostic process, its sensitivity and specificity are limited. Small lesions on the ovaries and the fimbriae of the fallopian tubes cannot be adequately visualized by TVS. In the PLCO trial, the PPV of TVS was found to be as low as 1% [22]. The specificity limitations of CA‐125 need to be supplemented by combining it with imaging techniques, and transvaginal sonography (TVS) can assist in differential diagnosis through structural visualization. Additionally, surgical exploration followed by pathological examination under a microscope is regarded as the gold standard for the definitive diagnosis of OC. However, surgical exploration, which relies on visual and tactile assessment, carries the risk of missing subtle lesions due to its inherent limitations. Moreover, its invasive nature and associated complications restrict its applicability in certain clinical scenarios [23]. Similarly, the accuracy of pathological examination is highly dependent on the quality of the sampled tissue. Sampling errors and time delays may compromise the results. Furthermore, significant intratumoral heterogeneity often exists within ovarian tumors, and a single‐site biopsy sample may not fully represent the characteristics of the entire tumor. This approach lacks the ability to adequately capture tumor heterogeneity and the evolution of the cancer genome, potentially leading to incomplete or biased diagnostic conclusions [24]. These limitations underscore the need for more comprehensive and precise diagnostic strategies to improve the accuracy and reliability of OC diagnosis. These limitations of conventional detection modalities have propelled the application of liquid biopsy technologies in the detection and monitoring of OC. Figure 1 summarizes the advantages and challenges of two core liquid biopsy technologies: ctDNA and CTCs. In contrast, liquid biopsy has the potential to capture molecular information derived from the entire tumor tissue, thereby overcoming, in certain cases, the challenges posed by tumor heterogeneity (or multiple metastatic lesions) [26]. Additionally, it enables real‐time monitoring of disease progression and treatment response through repeated sampling over short intervals. Compared to traditional tissue biopsy, liquid biopsy offers a noninvasive, rapid, and comprehensive approach, holding promise to usher in a new era in clinical oncology [13]. Schematic of clinical examination and exploratory diagnostic approaches for ovarian cancer. (1) Routine clinical examinations: ① Imaging examination: As a primary screening modality, transvaginal ultrasound facilitates lesion localization. ② Pathology examination: Pathological assessment of tissues collected from surgery or biopsy is universally recognized as the gold standard for definitive diagnosis. ③ Serum tumor marker detection: Serum CA‐125, a nonspecific biomarker, is widely used for initial screening and longitudinal follow‐up of disease progression. (2) Exploratory diagnostic approaches: ④ Liquid biopsy: Liquid biopsy platforms, including CTCs, TEPs, exosomes and ctDNA, are mainly applied for post‐treatment surveillance and are under exploration for early diagnosis. At present, liquid biopsy has not been adopted in routine clinical diagnosis, as it remains in translational and preclinical research [25]. Additionally, the clinical utility of ctDNA has not been fully confirmed and is yet to be widely used in standard clinical settings. Clinical Application and Technical Research Progress of Liquid Biopsy in Ovarian Cancer ctDNA and CTCs are the two most clinically valuable core biomarkers for liquid biopsy in OC (see Figure 2). Circulating cell‐free DNA (cfDNA), also referred to as cell‐free DNA, denotes DNA molecules that are not enclosed by cell membranes and are present in plasma or other bodily fluids. These molecules typically range in length from 150 to 200 base pairs (bp) and are primarily released into the circulation through passive mechanisms such as apoptosis and necrosis, as well as through active secretion from living cells via extracellular vesicles (EVs) [17]. ctDNA represents a subset of cfDNA that originates from cancer cells and is considered a specialized subtype of cfDNA. Although ctDNA generally constitutes a minor fraction of total cfDNA, it is more fragmented than nonmutated cfDNA, with the highest enrichment of fragments observed between 90 and 150 bp [27, 28]. Advantages and challenges of circulating tumor DNA and circulating tumor cells. In contrast to conventional serum biomarkers and imaging modalities, ctDNA‐based assays, which rely on the detection of molecular signatures, have opened up new avenues for the early detection of OC. ctDNA is increasingly important in oncology, with its diverse applications continuously being explored. In cancer management, it enables minimally invasive tumor assessment for diagnosis, prognosis, and treatment (e.g., guiding BRCA1/2‐targeted therapy in OC [29, 30]), detects MRD to prevent metastasis, and monitors tumor evolution, drug resistance and disease progression in metastatic settings. In clinical trials, it screens patients, stratifies risk, evaluates responses, enriches populations via MRD to reduce trial size and duration [31]. For drug development, it accelerates research via high‐risk cohort enrichment, shows potential as an unvalidated early regulatory endpoint. Notably, the U.S. Food and Drug Administration (FDA) has issued guidance to support the use of ctDNA in drug development for early solid tumors [32]. In OC, FoundationOne Liquid CDx (F1CDx), a liquid biopsy‐based ctDNA detection technology, was approved by the U.S. FDA in 2020 for detecting BRCA1/2 mutations in the blood to guide the medication decision of PARP inhibitor Rubraca (rucaparib). Clinical validation data from its FDA approval studies demonstrated a sensitivity of 94.4% (95% CI: 86.3%–98.5%) and a specificity of > 99.9% (95% CI: 99.9%–100.0%) for BRCA1/2 mutation detection in OC, providing a critical basis for the rational clinical use of PARP inhibitors [33]. CTCs are malignant cells shed from primary tumors or metastatic lesions into the bloodstream, where they circulate [34]. These cells may exist as single entities or aggregate into clusters [35]. The presence of CTCs is closely associated with cancer metastasis, as they can disseminate via the bloodstream to distant organs and seed new tumors [36]. Compared with ctDNA, CTCs are more dedicated to reflecting the invasive and metastatic potential of OC in clinical practice [37]. They can directly manifest the hematogenous dissemination ability of tumor cells and predict the risks of distant metastasis and disease recurrence [38, 39]. In contrast, ctDNA is better at revealing tumor molecular features and dynamic alterations, precisely capturing genomic information including gene mutations and copy number variations, and achieving real‐time monitoring of treatment response and development of drug resistance [40]. These two biomarkers are mutually complementary and irreplaceable. Their combined detection enables comprehensive evaluation of tumor biological behaviors, thereby providing a more sufficient evidence‐based basis for individualized diagnosis and treatment of OC. The following sections respectively elaborate on the technical characteristics and clinical applications of ctDNA and CTCs. Circulating Tumor DNA (ctDNA) To contextualize the clinical utility of ctDNA highlighted above, a clear understanding of its definition, biological characteristics, and release mechanisms relative to circulating cfDNA is essential. This foundational knowledge further supports the interpretation of OC‐specific ctDNA research findings and their translational implications. ctDNA is derived from passive and/or active release by tumor cells and carries genetic mutations or other alterations that match those of the tumor cells. However, the mechanisms underlying both active and passive release of ctDNA remain incompletely understood. It is widely accepted that apoptosis and necrosis of tumor cells constitute the primary sources of ctDNA [27], with a smaller proportion being released by CTCs [41]. The rapid proliferation of tumor cells can induce localized hypoxia and metabolic stress, ultimately leading to apoptosis or necrosis of tumor cells. These processes can result in the passive release of cellular contents into the extracellular space [42, 43]. Compared to healthy individuals, cancer patients exhibit significantly elevated levels of cfDNA in their blood, a phenomenon that has been reported in patients with breast cancer, colorectal cancer, pancreatic cancer, and gastroesophageal cancer [44]. In OC, ctDNA levels were first reported in 2012 [45]. The concentration of ctDNA mutations increases with advancing tumor stage, with significantly higher levels observed in stage III/IV patients compared to stage I (p = 0.025) and stage II (p = 0.007) cases [46]. Additionally, ctDNA levels correlate with tumor volume and morphology [47]. Furthermore, ctDNA can be derived from both primary and metastatic lesions, exhibiting a strong correlation with the molecular pathological features of OC [48]. For high‐grade serous ovarian cancer (HGSOC), TP53 mutation is an extremely common genetic alteration, making this gene a core target for liquid biopsy [49]. In general, ctDNA detection performance is largely affected by tumor burden rather than technical limitations [48, 50]. Chemotherapy‐induced tumor shrinkage will reduce ctDNA abundance and lower detection positivity. Combining detection of TP53 mutations with copy number variations (CNVs) can effectively improve the overall detection rate and compensate for such deficiencies. Accordingly, ctDNA carrying TP53 mutations shows great potential for dynamic monitoring of treatment response in HGSOC [51, 52]. Detection and Analytical Methods In OC, ctDNA detection methods are broadly classified into two categories: polymerase chain reaction (PCR)‐based platforms and next‐generation sequencing (NGS)‐based approaches. PCR‐based methods primarily include digital PCR (dPCR), droplet digital PCR (ddPCR), and Tagged‐Amplicon Sequencing (TAm‐Seq). These PCR‐driven techniques focus on detecting predefined specific anomalies in the genome and demonstrate advantages in identifying low‐abundance ctDNA due to their high sensitivity and specificity [53]. Additionally, they are relatively time‐efficient and cost‐effective. NGS‐based methods encompass whole genome sequencing (WGS), whole exome sequencing (WES), hybrid capture‐based panels, and amplicon‐based sequencing. NGS technologies do not require prior genomic preselection and enable simultaneous detection of mutations across multiple genes. They are widely employed for comprehensive genomic mutation profiling and monitoring in cancer research [54, 55]. In OC research and clinical applications, hybrid capture panels (such as FoundationOne) are commonly used to detect key genes including TP53, BRCA1/2, PIK3CA, and KRAS. These genes are not only closely associated with the pathogenesis of OC (e.g., TP53 mutation is a core event driving the development of high‐grade serous OC), but also provide important evidence for targeted therapy (for instance, patients with BRCA mutations can benefit from PARP inhibitor treatment) [56]. On the other hand, amplicon‐based sequencing focuses on known driver mutations in OC (such as TP53), and is suitable for rapid clinical screening scenarios. Its detection sensitivity is affected by factors such as the type of test samples (naive or post‐chemotherapy), the technical platform, and the variant allele frequency (VAF) of the target genes. The sensitivity can reach 72.2% in naive patients and 42.9% in post‐chemotherapy patients [51]. However, these approaches are comparatively time‐intensive and necessitate specialized bioinformatics expertise for data analysis (see Table 1). TABLE 1Detection and analytical methods for ctDNA in OC.MethodSensitivitySpecificityAdvantagesLimitationsClinical applicationsReferences Nonenriched next‐generation sequencing methods WGS a Perform high‐throughput sequencing of the entire genome or exome regions to detect DNA sequence variations93.8%88.9% Comprehensive genomic analysis Poor probe design can affect accuracyIn patients with low tumor burden, false‐negative results may occur due to low levels of tumor‐released DNA. Identify targeted mutationsIdentify drug resistance and its genotyping [57] Target‐enriched next‐generation sequencing methods Hybridization Capture(e.g., WES a )Capture the target region using specific probes and perform sequencing analysis.~100% (stage IV)Not mentioned Capture wide genomic rangesUltra‐sensitive detectionIdentify novel mutations Lower detection frequency in ctDNADifferent frequencies of gene rearrangementsCost higher and time‐consuming Guide targeted therapyAnalysis of Multiple Gene Mutations [58]Amplicon SequencingCarry out sequencing after amplifying the target region by Polymerase Chain Reaction (PCR)83.3%High High accuracy for hotspot mutationSave cost and detection timeNeed fewer DNA sample inputs Cannot detect large structural variationOnly detect preset gene sitesEasy to appear PCR false positive Detection of Known MutationsClinical Rapid Screening [59] Polymerase chain reaction (PCR)‐based methods Targeted assaysDetect and analyze specific genes or regionsHighHigh Can detect structural variations, single‐nucleotide variants (SNVs), small duplications, insertions, and indelsShort turnaround timeCapable of quantitative analysis Low sensitivity in early‐stage cancer detectionOnly focus on the pre‐defined regions, potentially missing other targetable mutationsResistance mutations may be overlooked Identifying the pre‐specified target of significance (e.g., EGFR)Screening of High‐risk PopulationsMonitoring of Tumor Recurrence [60]Quantifiler Human Quantification Kit a Accurately determine the content of human DNA in the sample77%96% High specificityPrognostic value Limited sensitivityThreshold‐dependentInterference from surgery DiagnosisTreatment monitoringPrognosisSurgical monitoringDisease progression tracking [61]Abbreviations: WES, Whole Exome Sequencing; WGS, Whole Genome Sequencing. a Commercially available technologies. Detection and analytical methods for ctDNA in OC. Comprehensive genomic analysis Comprehensive genomic analysis Poor probe design can affect accuracy Poor probe design can affect accuracy In patients with low tumor burden, false‐negative results may occur due to low levels of tumor‐released DNA. In patients with low tumor burden, false‐negative results may occur due to low levels of tumor‐released DNA. Identify targeted mutations Identify targeted mutations Identify drug resistance and its genotyping Identify drug resistance and its genotyping Capture wide genomic ranges Capture wide genomic ranges Ultra‐sensitive detection Ultra‐sensitive detection Identify novel mutations Identify novel mutations Lower detection frequency in ctDNA Lower detection frequency in ctDNA Different frequencies of gene rearrangements Different frequencies of gene rearrangements Cost higher and time‐consuming Cost higher and time‐consuming Guide targeted therapy Guide targeted therapy Analysis of Multiple Gene Mutations Analysis of Multiple Gene Mutations High accuracy for hotspot mutation High accuracy for hotspot mutation Save cost and detection time Save cost and detection time Need fewer DNA sample inputs Need fewer DNA sample inputs Cannot detect large structural variation Cannot detect large structural variation Only detect preset gene sites Only detect preset gene sites Easy to appear PCR false positive Easy to appear PCR false positive Detection of Known Mutations Detection of Known Mutations Clinical Rapid Screening Clinical Rapid Screening Can detect structural variations, single‐nucleotide variants (SNVs), small duplications, insertions, and indels Can detect structural variations, single‐nucleotide variants (SNVs), small duplications, insertions, and indels Short turnaround time Short turnaround time Capable of quantitative analysis Capable of quantitative analysis Low sensitivity in early‐stage cancer detection Low sensitivity in early‐stage cancer detection Only focus on the pre‐defined regions, potentially missing other targetable mutations Only focus on the pre‐defined regions, potentially missing other targetable mutations Resistance mutations may be overlooked Resistance mutations may be overlooked Identifying the pre‐specified target of significance (e.g., EGFR) Identifying the pre‐specified target of significance (e.g., EGFR) Screening of High‐risk Populations Screening of High‐risk Populations Monitoring of Tumor Recurrence Monitoring of Tumor Recurrence High specificity High specificity Prognostic value Prognostic value Limited sensitivity Limited sensitivity Threshold‐dependent Threshold‐dependent Interference from surgery Interference from surgery Diagnosis Diagnosis Treatment monitoring Treatment monitoring Prognosis Prognosis Surgical monitoring Surgical monitoring Disease progression tracking Disease progression tracking Abbreviations: WES, Whole Exome Sequencing; WGS, Whole Genome Sequencing. Commercially available technologies. Early Diagnosis Early screening is critical for improving survival rates in OC patients. Despite the availability of various screening methods and biomarkers, the sensitivity and specificity of single‐modality screening remain limited. In a retrospective study of 799 patients, only 20% of abnormal CA‐125 results in women suspected of malignancy, particularly OC, were attributed to OC, with the majority being false‐positive findings [62]. The high false‐positive rate and suboptimal sensitivity and specificity of CA‐125 may lead to unnecessary invasive procedures. Emerging evidence suggests that ctDNA testing, as a potential noninvasive diagnostic tool, may offer more reliable diagnostic value compared to traditional imaging and serum tumor markers [57]. Several studies have demonstrated that cfDNA levels are significantly elevated in OC patients compared to those with benign ovarian tumors or healthy individuals. Furthermore, cfDNA levels in patients with stage III/IV OC are markedly higher than in those with stage I/II disease [63, 64]. Recent studies and meta‐analyses indicate that ctDNA exhibits high sensitivity (84%) and specificity (91%) for OC diagnosis, with an area under the receiver operating characteristic (ROC) curve (AUC) of 94% [65]. In another study, blood samples from 42 OC patients were analyzed using targeted error‐correction sequencing (TEC‐Seq) to detect tumor‐specific alterations in DNA molecules. Detectable driver gene mutations were identified in 71% of patients [66]. Notably, ctDNA analysis can identify specific genetic mutations in OC patients, such as TP53 and BRCA1/2 [66]. Crucially, accumulating evidence has demonstrated substantial concordance between ctDNA‐detected genetic alterations and matched tumor tissue genomic profiles. A systematic review including 19 studies reported concordance ranging from moderate to strong (r = 0.428–0.771) across different analytical platforms [40]. For instance, Vanderstichele et al. reported that copy number variation profiles in plasma cfDNA were highly representative of those in paired tumor tissue in high‐grade serous epithelial OC, with a Spearman correlation coefficient of 0.67 [67]. These findings indicate that ctDNA can reliably capture the genetic landscape of OC. Among these aberrations, TP53 mutation dominates in high‐grade serous ovarian carcinoma, with a prevalence exceeding 96% [68], and it plays a vital role in disease development. ctDNA‐based TP53 mutation detection has demonstrated clinical utility in the diagnosis of HGSOC, with its diagnostic sensitivity varying significantly across different treatment statuses. In treatment‐naïve patients with advanced FIGO stage IIB‐IV disease, Zelisse et al. [51] reported a sensitivity of 72.2%. In patients with recurrent disease, Parkinson et al. [69] reported a sensitivity of 84% (n = 51), while Cheng et al. [70] found a sensitivity of 81.8% in those with platinum‐resistant recurrent OC. In patients who received two cycles of neoadjuvant chemotherapy, Zelisse et al. [51] documented a significant decrease in sensitivity to 42.9% (p = 0.043). Notably, Cavina et al. [71] reported an overall sensitivity of 70% and a specificity of 100% with low‐grade serous ovarian cancer (LGSOC) serving as the negative control group in a mixed cohort of treatment‐naïve and recurrent patients. Among the applied technologies, NGS with molecular barcoding and dPCR exhibit superior detection performance in low tumor burden samples, enabling effective capture of trace mutation information [72, 73, 74]. Beyond diagnostic application, this detection approach also supports real‐time surveillance of treatment response and disease recurrence. However, its limitations cannot be overlooked: the detection sensitivity is only 36.8%–52.6% in stage I patients; the false‐negative rate reaches as high as 41.2%–47.4% in cases of low tumor burden (e.g., tumor diameter < 1 cm) or extremely low ctDNA concentrations post‐chemotherapy; meanwhile, tumor heterogeneity and technical differences across platforms also interfere with test results [75]. To address these limitations, DNA methylation detection has emerged as a pivotal research direction for breaking the bottleneck in early OC diagnosis, owing to its core advantages of early occurrence during tumorigenesis [76], high tissue specificity, and stable signals [77]. A recent study directly comparing methylation‐based and mutation‐based ctDNA detection approaches in serous ovarian adenocarcinoma found that methylation‐based testing identified ctDNA in 73% of post‐treatment samples where the mutation‐based method detected none (16/22 positive vs. 0/22), underscoring the superior sensitivity of methylation analysis in low tumor burden scenarios [78]. Notably, Liang et al. developed and validated an 18‐differentially methylated region (DMR)‐based cfDNA ovarian cancer detection model (OC‐D model), which achieved a stage‐specific sensitivity of 83.3% for stage I and 85.7% for stage II disease in an independent external validation cohort [79]. Furthermore, a multi‐center retrospective cohort study demonstrated that the combined mutation‐methylation panel achieved an area under the curve (AUC) of 0.91 (95% CI 0.87–0.95), with a statistically significant incremental gain of 0.05 in AUC compared to mutation‐only assays, confirming the synergistic diagnostic value of integrating both modalities [80]. Thus, the complementary integration of ctDNA gene mutation detection and DNA methylation profiling can synergistically improve the early diagnostic accuracy of OC. However, clinical translation of integrated ctDNA mutation and methylation detection for early OC detection faces challenges. Consistent with the above biological characteristics, ctDNA levels are modulated by tumor burden, treatment interventions, and individual differences [81]. Standardization of pre‐analytical and analytical protocols remains the most critical unmet need. A landmark guideline demonstrated that pre‐analytical variables (including blood collection, plasma separation, cfDNA extraction, and bisulfite conversion) constitute a dominant source of variability in ctDNA methylation detection results [82]. Additionally, the most promising OC methylation markers (including the 18‐DMR panel in the OC‐D model) have only been validated in retrospective cohorts, and large‐scale prospective clinical trials are still lacking [83]. Furthermore, clonal hematopoiesis of indeterminate potential (CHIP) is a critical biological confounder in ctDNA‐based early detection. Age‐related clonal expansion of hematopoietic cells can release nontumor‐derived mutations into plasma, leading to false‐positive results when variant allele frequencies are low [84, 85]. Moreover, conventional short‐read NGS platforms have limited sensitivity for large genomic rearrangements (LGRs) in large genes such as BRCA1/2, a challenge further compounded by the highly fragmented nature of cfDNA, potentially resulting in missed pathogenic variants [86, 87]. Moving forward, elucidating these multifaceted factors affecting diagnostic performance and establishing standardized protocols and prospective validation frameworks are essential for translating integrated ctDNA findings into clinical decision‐making [88]. Addressing these challenges is pivotal for advancing ctDNA‐based strategies in early OC diagnosis and personalized management. Treatment Monitoring Studies indicate that changes in ctDNA levels can serve as an indicator for assessing early responses to systemic therapies. For instance, one study found that patients with increased ctDNA levels after the first chemotherapy cycle were more likely to exhibit a favorable response to chemotherapy [89]. Additional research demonstrates that analyzing ctDNA mutations, copy number variations (CNVs), and disease‐specific gene expression profiles may predict and evaluate patient responses to immune checkpoint inhibitor therapy [55, 90, 91]. Another study revealed that sWGS of ctDNA enables monitoring of disease recurrence and prediction of progression following platinum‐based treatment [92]. These findings highlight the critical role of ctDNA in elucidating tumor biology and guiding personalized therapeutic strategies. ctDNA is also utilized to predict post‐treatment disease‐free survival (DFS) and progression‐free survival (PFS), thereby evaluating therapeutic efficacy. Research has shown that elevated ctDNA levels after the first chemotherapy cycle correlate with improved DFS, potentially indicating favorable chemotherapeutic outcomes [41]. A separate study demonstrated that serial ctDNA testing using small‐panel NGS can detect MRD at baseline and during 6‐month follow‐ups, predicting PFS in OC patients. The disappearance of pathogenic mutations detected at baseline during follow‐up is associated with better survival outcomes. These observations underscore the potential value of dynamic ctDNA monitoring in predicting chemotherapy responses, tracking disease progression, and adjusting treatment strategies based on mutational evolution [66]. ctDNA analysis further aids in monitoring and evaluating acquired resistance to specific therapies. Approximately 25% of OC patients harbor pathogenic BRCA1 or BRCA2 mutations, which are associated with improved responses to poly (ADP‐ribose) polymerase 1 (PARP1) inhibitor therapy compared to wild‐type individuals [93]. However, secondary intragenic reversion mutations that restore protein function contribute to clinically significant rates of acquired resistance. Notably, ctDNA analysis can detect BRCA1/2 reversion mutations induced by platinum‐based chemotherapy and PARP inhibitors, demonstrating its clinical utility in predicting chemoresistance in recurrent OC [94]. Studies have also shown that analyzing ctDNA‐derived CNVs before and after chemotherapy can distinguish between neoadjuvant chemotherapy‐sensitive and chemotherapy‐resistant OC patients [90]. Prognostic Evaluation ctDNA has demonstrated significant value in prognostic assessment for OC patients. Multiple studies indicate that the presence or absence of ctDNA, along with its specific mutational profiles, can serve as critical predictors of survival rates and disease recurrence. In an analysis of 51 patients with stage I‐IV OC, higher cfDNA concentrations were significantly associated with worse progression‐free survival (PFS) in all patients and in stage III‐IV subgroups (p = 0.01 and p = 0.005, respectively) [54]. Furthermore, a separate meta‐analysis incorporating 26 studies demonstrated that elevated ctDNA levels in EOC were significantly associated with worse progression‐free survival (HR = 5.31, 95% CI 2.14–13.17, p < 0.001) and overall survival (HR = 2.98, 95% CI 1.86–4.76, p < 0.0001) [95]. Furthermore, ctDNA levels exhibit strong correlations with traditional serum CA‐125 levels and CT imaging findings. However, ctDNA can detect cancer presence even in cases where CT scans are negative [57], suggesting its superior potential for identifying MRD and early recurrence in postoperative OC patients. MRD refers to the persistence of residual tumor cells post‐treatment, which is often linked to relapse and poor prognosis [96]. Compared to conventional serum biomarkers and imaging modalities, ctDNA provides earlier detection of recurrence, a critical advantage for a highly lethal malignancy like OC. In one study, serial ctDNA analysis using whole‐exome sequencing (WES) to track somatic mutations in plasma samples from 22 patients post‐definitive therapy detected recurrence with 100% sensitivity and specificity, achieving a median lead time of 135 days (range: 45–387 days) compared to standard CT imaging [97]. Joonatan Sipola et al. reported that tumor‐informed cfDNA analysis detected residual disease in 63 EOC patients post‐treatment. ctDNA identified progression in all 18 cases at progression, with 12/18 patients showing earlier detection via ctDNA than standard monitoring (median lead time: 5.9 months) [98]. Another study involving postoperative plasma ctDNA testing in 48 women with serous OC found detectable ctDNA in all patients with visible residual disease [99], which underscores its favorable sensitivity and specificity in MRD assessment. Finally, dPCR‐based quantification of preoperative plasma ctDNA levels revealed that patients with higher baseline ctDNA (≥ 10 mutant copies/mL) had significantly worse OS [46]. Additionally, detectable postoperative ctDNA (a marker of MRD) has been associated with elevated recurrence risk [100]. In summary, ctDNA as a liquid biopsy biomarker exhibits substantial potential in OC diagnosis, monitoring, and prognostic evaluation. Circulating Tumor Cells and Circulating Tumor Cells Clusters CTC clusters, composed of multiple aggregated CTCs, exhibit enhanced survival capabilities and greater metastatic potential compared to single CTCs. Studies indicate that CTC clusters are up to 50‐fold more likely to promote metastasis than individual CTCs [36, 101]. Two distinct types of CTC clusters have been identified: homotypic clusters and heterotypic clusters. Homotypic clusters consist exclusively of tumor cells with similar phenotypic and gene expression profiles, reflecting intratumoral homogeneity and potentially correlating with aggressive biological behaviors such as invasiveness and metastatic propensity [102]. In contrast, heterotypic clusters contain not only tumor cells but also nonmalignant cells, including platelets, neutrophils, macrophages, myeloid‐derived suppressor cells (MDSCs), or cancer‐associated fibroblasts (CAFs) [35, 103]. These nontumor components provide protective microenvironments that enhance CTC survival and metastatic efficiency by resisting apoptosis and immune surveillance [103, 104]. For instance, platelets facilitate CTC survival and immune evasion by adhering to capillary walls [105], while immune cells within clusters may modulate tumor immune escape mechanisms and therapeutic responses [35, 106, 107, 108]. In OC research, the detection of CTCs not only provides critical insights for early diagnosis and prognostic evaluation but also aids in treatment selection, therapeutic monitoring, and identification of drug targets [109, 110]. Technologies for CTC Enrichment and Isolation The detection of CTCs primarily relies on two methodological approaches: immunocytochemical (ICC)‐based techniques and reverse transcription‐polymerase chain reaction (RT‐PCR)‐based techniques. Common platforms include the CellSearch system [111], immunomagnetic separation, ISET (Isolation by SizE of Tumor cells) system, SACA (Silicon Microfluidics Antibody‐Capturing Chip) chips, and image analysis methods. Among these, the EpCAM‐dependent CellSearch system remains the only U.S. Food and Drug Administration (FDA)‐approved method for clinical CTC enumeration [112]. However, its performance in EOC is significantly limited by the high prevalence of epithelial‐mesenchymal transition (EMT) in this disease, which generates EpCAM‐negative CTCs that evade antibody‐mediated capture. To systematically evaluate the diagnostic, prognostic, and predictive utility of distinct CTC detection technologies specifically in OC, we have compiled a comprehensive summary of published clinical evidence, as detailed in Table 2. TABLE 2Detection technologies for CTC in OC.Patient characteristics (n)Detection methodCapture biomarkersPositivity criteriaPositivity rate a (%)Clinical significanceReferencesRelapsed/metastatic (216)CellSearch systemEpCAM (capture); CK8/18/19; CD45− ≥ 2 CTCs/7.5 mL blood14.4CTCs ≥ 2 associated with shorter PFS (3.2 vs. 6.6 months, p = 0.0024) and OS (12.chnologies for CTCs enrichmevs 20.6 months, p = 0.0017); independent prognostic factor (HR = 1.58)[113]Newly diagnosed/recurrent (78)CellSearch systemEpCAM (capture); CK; CD45− EpCAM+/CK+/CD45−/DAPI+, ≥ 2 CTCs> 80No significant correlation between CTCs and PFS/OS (p = 0.88/p = 0.40); no association with CA125 (p = 0.49)[114]Malignant/benign (49)CellSearch systemEpCAM (capture); CK8/18/19; CD45− ≥ 1 CTC/7.5 mL blood Malignant: 17.2% (primary)/80% (metastatic) Benign: 0 100% PPV for malignancy, but low sensitivity (25.7%); metastatic CTCs significantly higher than primary (p < 0.05)[115]OC patients (43)CellSearch systemEpCAM (capture); CK8/18/19; CD45− ≥ 1 CTC/7.5 mL blood26.0CTCs positivity associated with shorter OS and PFS (p < 0.01); aids in chemotherapy resistance assessment[116]OC patients (118)MetaCell size‐based separation (8 μm membrane filtration)No antibody labeling (physical size‐based)Diameter ≥ 10 μm, high nuclear‐cytoplasmic ratio, irregular morphology65.2Correlated with ascites and peritoneal metastasis (p < 0.05); no correlation with CA125[117]OC patients (30)Tapered‐slit filter (TSF) platformNo surface markers (physical properties‐based)DAPI+/CD45−/CK9+/EpCAM+ + morphological criteria (high N/C ratio, irregularity) Preoperative: 76.7% Postoperative: 57.1% Postoperative CTCs associated with trend toward shorter PFS (p = 0.077); higher positivity in lymph node metastasis (100% vs. 30.0%, p = 0.010)[118]Malignant/benign (71)CAM enrichment + flow cytometryEpCAM, ESA, pan‐CK; CD45− CAM+/Epi+, excluding CD45+ cells60.6Higher positivity in advanced vs. early stages (p < 0.001); CTCs positivity correlated with shorter DFS (15 vs. 35 months, p = 0.042); positive correlation with CA125 (r = 0.309)[119]EOC/benign (129)CAM enrichment + flow cytometryEpi+ (EPCAM, CA125, etc.); HL− (CD45, CD66b); CAM adhesion/invasion activity≥ 5 iCTCs/1.0 mL blood83Early diagnosis PPV 77.8% (CA125: 61.6%); iCTCs correlated with OS/PFS (p < 0.05); superior specificity to CA125[120]EOC patients (31)CAM enrichment + flow cytometryEpi+ (EPCAM, CA125, etc.); HL− (CD45, CD66b); CAM adhesion/invasion activity≥ 5 iCTCs/1.0 mL blood85.3Earlier progression prediction than CA125 (sensitivity 79.5% vs. 67.6%); effective in CA125‐normal patients[121]Newly diagnosed/recurrent (54)Multiantibody microfluidic chip (nanoroughened surface + conductivity)EpCAM, TROP‐2, EGFR, vimentin, N‐cadherinCTCs: EpCAM+/DAPI+/CD45−; CTC clusters: 2–30 cancer cell aggregates98.1CTCs ≥ 3 associated with shorter PFS (14 vs. 23 months, p = 0.013); cluster positivity correlated with platinum resistance (p = 0.001)[122]Malignant/benign (61)Microfluidic chip + immunofluorescence (size‐based + multi‐marker)CD45−; EpCAM, panCK, CK7, vimentin; HE4≥ 0.5 CTCs/1.0 mL blood73.3Diagnostic AUC = 0.716, sensitivity 73.3% (CA125: 56.7%); no correlation with CA125, especially in CA125‐normal patients[123]EOC patients (109)Immunomagnetic bead enrichment + multiplex RT‐PCR (EpCAM/HER2/MUC1)EpCAM, HER2, MUC1 (capture); WT1, P16, PAX8 (mRNA detection)Any gene PCR product > 0.3 ng/μL (3× healthy volunteer mean)90% (newly diagnosed), 91% (post‐treatment)Early OC positivity 93% (CA125: 64%); EpCAM/HER2 overexpression correlated with chemotherapy resistance (p < 0.05); EpCAM overexpression associated with shorter OS (p = 0.041)[124]EOC patients (160)Immunomagnetic bead enrichment + multiplex RT‐PCR (EpCAM/MUC1/WT1)EpCAM, MUC1 (capture); WT1 (mRNA detection)Logistic regression model Y ≥ 0.617 (based on mRNA concentrations)Sensitivity 79.4%, specificity 92.2%Earlier detection than CA125 (74.5% vs. 58.2%); CTCEpCAM+/MUC1+ correlated with chemotherapy resistance (p < 0.05); CTCMUC1+ predictive of poor OS (p = 0.043)[125]EOC patients (152)CanPatrol CTC enrichment (RNA‐ISH)EpCAM, CK8/18/19; Vimentin, Twist; CD45− EMT status‐based (E/M/mixed phenotype)Not reportedM‐CTC percentage correlated with recurrence (HR = 1.098, p = 0.009); nomogram predicted recurrence risk (C‐index = 0.913/0.874)[126]OC/benign (56)SE‐iFISH (negative enrichment + immunofluorescence + iFISH)CD45−; CD31−; CA125, HE4DAPI+/CD45−/CD31−/(CA125+ or HE4+ or Chr8 aneuploidy)OC: 95%, Benign: 94.4%Triploid/tetraploid CTCs significantly increased in OC (p < 0.01); combined detection optimal (AUC = 0.853)[127]Abbreviations: AUC, Area Under the Curve; Chr8, Chromosome 8; CTCs, Circulating Tumor Cells; DFS, Disease‐Free Survival; EMT, Epithelial‐Mesenchymal Transition; EOC, Epithelial Ovarian Cancer; HE4, Human Epididymis Protein 4; iCTCs, Invasive Circulating Tumor Cells; iFISH, Interphase Fluorescence In Situ Hybridization; N/C ratio, Nuclear‐Cytoplasmic Ratio; OC, Ovarian Cancer; OS, Overall Survival; PFS, Progression‐Free Survival; PPV, Positive Predictive Value; RNA‐ISH, RNA In Situ Hybridization. a This table summarizes the most relevant clinical studies on CTC detection in OC published to date, providing a head‐to‐head comparison of different technologies in terms of positivity rate, prognostic value, predictive utility for chemotherapy response, and diagnostic performance. Detection technologies for CTC in OC. Malignant: 17.2% (primary)/80% (metastatic) Benign: 0 Preoperative: 76.7% Postoperative: 57.1% Abbreviations: AUC, Area Under the Curve; Chr8, Chromosome 8; CTCs, Circulating Tumor Cells; DFS, Disease‐Free Survival; EMT, Epithelial‐Mesenchymal Transition; EOC, Epithelial Ovarian Cancer; HE4, Human Epididymis Protein 4; iCTCs, Invasive Circulating Tumor Cells; iFISH, Interphase Fluorescence In Situ Hybridization; N/C ratio, Nuclear‐Cytoplasmic Ratio; OC, Ovarian Cancer; OS, Overall Survival; PFS, Progression‐Free Survival; PPV, Positive Predictive Value; RNA‐ISH, RNA In Situ Hybridization. This table summarizes the most relevant clinical studies on CTC detection in OC published to date, providing a head‐to‐head comparison of different technologies in terms of positivity rate, prognostic value, predictive utility for chemotherapy response, and diagnostic performance. Despite advancements in CTC detection technologies, several challenges remain particularly pronounced in OC. First, the extreme rarity of CTCs in peripheral blood (approximately 1–10 CTCs per milliliter of blood) [128], renders their detection technically demanding [129]. Unlike breast and prostate cancers where hematogenous spread is dominant, OC primarily metastasizes via intraperitoneal dissemination, resulting in even lower baseline CTC counts, especially in early‐stage disease. Furthermore, CTCs exhibit substantial heterogeneity and diversity. Marker expression varies across cancer types and even within the same cancer at different stages [34]. A large proportion of OC CTCs undergo EMT, downregulating epithelial markers such as EpCAM and upregulating mesenchymal markers such as vimentin [130]. This phenotypic plasticity leads to significant underdetection by EpCAM‐only enrichment strategies, as evidenced by the highly variable positivity rates of the CellSearch system in OC studies (14.4%–80%) shown in Table 2. In contrast, multi‐marker, label‐free, or negative enrichment approaches consistently achieve higher sensitivity (65.2%–98.1%) in the same patient population. Finally, the lack of standardized positivity criteria across different platforms has hindered clinical translation. As demonstrated in Table 2, studies employ varying thresholds (ranging from ≥ 1 CTC/7.5 mL to ≥ 5 iCTCs/1.0 mL) and different combinations of biomarkers, making direct cross‐study comparisons challenging. This highlights the urgent need for consensus guidelines to facilitate the clinical implementation of CTC testing in OC. Early Diagnosis While research on the application of CTCs in OC remains relatively limited compared to nonsmall cell lung cancer, breast cancer, and prostate cancer, recent advancements in micro‐ and nanotechnologies and biomedical engineering have significantly enhanced CTC detection rates in OC. Innovations such as MetaCell, Microfluidic systems, and cell size‐based physical methods enable precise manipulation and analysis of individual cells by controlling microenvironments and force fields at microscale levels. These technologies effectively overcome limitations imposed by variable surface antigen expression or epithelial‐mesenchymal transition (EMT) in CTCs [122, 131, 132]. For instance, a study utilizing a biotin‐doped polypyrrole (Ppy)‐coated microfluidic device [133] reported a CTC detection rate of 98.1% (53/54) in OC patients [122]. Efforts to combine multiple technologies have further improved detection efficiency and accuracy. One study demonstrated that combining the CellSearch system with the AdnaTest increased the positivity rate from 33% (CellSearch alone) to 50% [134]. Additionally, research by Zuo et al. revealed that miR‐181a, which is overexpressed in OC tissues compared to normal ovarian tissues and correlates with tumor stage and metastasis, may serve as a surrogate biomarker for early diagnosis when quantified in CTCs [134]. These findings collectively support the potential of CTCs as early diagnostic markers for OC. However, translating CTCs into clinical practice for early OC diagnosis faces challenges such as limited sample sizes, methodological complexity, and lack of standardization. Future efforts should focus on optimizing technical approaches and establishing standardized protocols to facilitate the clinical implementation of CTC‐based diagnostics in OC. Treatment Monitoring In the context of chemotherapeutic response, multiple studies indicate that CTCs can serve as a critical biomarker for evaluating treatment efficacy, with a reduction in CTC count typically correlating with favorable therapeutic outcomes. As a key component of liquid biopsy, CTCs exhibit high sensitivity to genotypic changes in tumors. Sequential genetic profiling and drug sensitivity testing of captured and cultured CTCs enable the detection of known tumor mutations and identification of novel mutations arising from tumor metastasis or molecularly targeted therapies. This approach allows continuous assessment of tumor progression and drug resistance mechanisms, which is challenging to achieve with traditional tissue biopsies [135, 136, 137, 138]. Tagged‐Amplicon Sequencing (TAm‐Seq), a technique validated in HGSOC patients, has demonstrated the ability to detect low‐frequency mutations in ctDNA [45]. In contrast, extracting sufficient DNA from CTCs remains technically challenging, limiting their utility in mutation detection compared to ctDNA [135]. A study targeting 51 actionable genes in cfDNA and CTC‐derived DNA (ctcDNA) from 20 gynecologic cancer patients identified 20 somatic variants in CTC samples, with TP53, BRCA1, TSC2, ERBB2, and PTCH1 being the most frequently mutated genes. Notably, distinct genetic alterations were observed in cfDNA and CTC samples, suggesting complementary roles for these analytes in generating comprehensive mutational profiles [139]. Overall, current research on the utility of CTCs in identifying common genetic mutations in OC patients remains limited. Larger‐scale prospective clinical trials are warranted to validate these findings and optimize their clinical implementation. Prognostic Evaluation CTCs demonstrate prognostic value in OC as noninvasive, sensitive biomarkers capable of providing critical insights into survival outcomes and disease progression risks. A meta‐analysis of 1422 OC patients revealed a significant association between CTC positivity and poorer overall survival (OS) (HR = 1.57, 95% CI 1.30–1.84) and progression‐free survival (PFS) (HR = 1.29, 95% CI 1.04–1.54) [38]. In another study, CTCs were quantified via PPIC transcript measurement using quantitative polymerase chain reaction (qPCR) and immunofluorescence (IF) staining in OC patients at baseline and 6 months post‐adjuvant therapy. The presence of CTCs post‐treatment emerged as an independent prognostic factor, correlating with increased recurrence risk and reduced five‐year survival rates [140]. However, conflicting findings from a separate study showed no significant changes in postoperative CTC counts among high‐grade OC patients, nor any association with PFS or OS [141]. This discrepancy may reflect limitations in the sensitivity and specificity of CTCs as prognostic markers or suggest variability in their clinical utility across different stages of OC. Emerging Modalities of Liquid Biopsy In addition to the aforementioned CTCs and circulating tumor DNA (ctDNA), emerging liquid biopsy modalities include enzyme Activity‐based Liquid Biopsy (EALB), tumor‐educated platelets (TEPs), circular RNA (circRNA), exosomes, and microRNAs (miRNAs). While these technologies have yet to be validated in large‐scale prospective clinical trials due to limited sample sizes, suboptimal study designs, and a lack of standardized protocols for sample collection, processing, and analysis, they have demonstrated significant potential in early diagnosis and prognostic evaluation [142], real‐time monitoring of therapeutic response [143], and providing comprehensive molecular portraits of disease [144]. Figure 3 shows the sample sources, molecular biomarkers and clinical applications of liquid biopsy in OC. Molecular biomarkers and liquid biopsies in Ovarian Cancer. Enzyme Activity‐based Liquid Biopsy (EALB) represents a type of functional biomarker detection technology with great potential for clinical translation. This technology accurately reflects the dynamic functional state of tumor proliferation and invasion by specifically capturing abnormally activated proteases (such as matrix metalloproteinases, cathepsins, etc.) in the tumor microenvironment. It stands in sharp contrast to biomarkers like tumor‐educated platelets (TEPs) and circular RNAs (circRNAs), which only provide static molecular snapshots [145]. Its core advantage lies in its high sensitivity to early‐stage, low‐burden tumors. Even when the ctDNA concentration is extremely low in the early stages of the tumor, if the tumor is invasively active, the activity level of the proteases it secretes can already increase significantly, providing crucial functional evidence for early diagnosis [146, 147]. More importantly, the tumor invasion potential indicated by protease activity can be combined with the gene mutation profile provided by ctDNA and the metastasis risk evaluated by CTCs to achieve a three‐dimensional comprehensive assessment of the tumor's “functional state + genotype + phenotype,” strongly supporting individualized treatment decisions. A study published by Covarrubias‐Zambrano O et al. in the journal Cells in 2025 further verified the clinical application value of this technology. The optical nanobiosensor based on few‐layer exfoliated graphene (G‐NBSs) they developed can specifically detect the activity of proteases such as MMP3 in serum by linking fluorescently labeled protease‐specific sequences and tetracarboxyphenyl porphyrin (TCPP). The detection limit of this detection system reaches the sub‐attomolar level (< 10−15 mol/L), and the detection accuracy for early‐stage OC is 94.5%, with both sensitivity and specificity being 0.94 [148]. Although this technology demonstrates significant advantages, it currently still faces key challenges such as insufficient standardization of the sensor array and stringent requirements for sample handling (fresh samples are required to avoid protease activity degradation). Overall, it is in the early stage of clinical translation, and its widespread clinical application still requires further large‐sample validation and technical optimization. TEPs are platelets “educated” through interactions with tumor cells. By absorbing and storing tumor‐associated molecules, including coding/noncoding RNAs and proteins, they acquire tumor‐specific molecular signatures [149]. TEPs contribute to the progression and dissemination of various solid tumors. Splicing‐derived TEP RNA signatures can provide specific information about cancer presence, location, and molecular characteristics [150]. In OC diagnosis, TEPs exhibit high accuracy. One study reported an 80% accuracy rate in distinguishing malignant from benign ovarian tumors using TEP‐based scoring [151]. In an international hospital‐based diagnostic study, 761 patients with histologically confirmed adnexal masses undergoing primary treatment (enrolled from September 2016 to May 2018 across nine medical centers) and 167 healthy controls were analyzed. In validation cohorts from China (VC1, VC2) and Europe (VC3), the performance of TEPs alone and combined with CA125 was as follows: TEPs alone: Area under the curve (AUC) values were 0.918 (combined cohorts), 0.923 (VC1), 0.918 (VC2), and 0.887 (VC3). TEPs+CA125: AUC values improved to 0.922 (combined), 0.955 (VC1), 0.939 (VC2), and 0.917 (VC3). Subgroup analyses further demonstrated the utility of TEPs in detecting early‐stage disease (AUC = 0.858), borderline tumors (AUC = 0.859), nonepithelial malignancies (AUC = 0.920), and differentiating OC from endometriosis (AUC = 0.899) [68]. Despite their significant potential, the clinical application of tumor‐educated platelets (TEPs) faces several challenges and limitations. First, the mechanisms underlying platelet “education” by tumor cells remain incompletely understood. Further research is required to elucidate how tumor cells reprogram platelets and the specific molecular pathways governing RNA splicing within TEPs [150, 152]. Second, TEP‐derived signals may be contaminated by nontumor cells, compromising specificity. Studies have shown that transcripts detected in TEPs could originate from nonplatelet cells, necessitating computational noise‐filtering algorithms to improve signal accuracy [152]. Finally, TEP detection relies on specialized technologies and infrastructure, such as high‐throughput sequencing and sophisticated bioinformatics pipelines, whose limited accessibility and high costs may hinder widespread clinical adoption [153]. Circular RNAs (circRNAs) are a unique class of noncoding RNA molecules produced through back‐splicing of precursor mRNAs, forming a covalently closed loop structure [154]. Unlike linear RNAs, circRNAs exhibit greater stability and tissue specificity [155, 156]. They exist as single‐stranded molecules and are detectable in various bodily fluids, including blood, saliva, and urine, and particularly ascites—a biofluid uniquely abundant in OC patients [156, 157]. Their high stability and accessibility in biofluids position circRNAs as promising tools for OC diagnosis, monitoring, prognosis, and therapeutic guidance [158]. Significant progress has been made in circRNA‐based liquid biopsy for OC. In plasma, several circRNAs have been identified as robust diagnostic biomarkers. For example, plasma circN4BP2L2 was significantly downregulated in EOC patients, with an area under the receiver operating characteristic curve (AUC) of 0.82 for distinguishing EOC from benign ovarian cysts and 0.90 for distinguishing EOC from healthy controls; notably, it could also differentiate early‐stage EOC from benign (AUC = 0.81) and healthy (AUC = 0.90) cohorts [159]. Another plasma circRNA, circBNC2, was also found to be downregulated in EOC, achieving an AUC of 0.879 for EOC versus benign tumors (sensitivity 96.4%, specificity 80.7%) and 0.923 for EOC versus healthy controls (sensitivity 95.2%, specificity 85.5%). Importantly, for early‐stage (FIGO I–II) EOC, circBNC2 yielded an AUC of 0.864 versus benign and 0.908 versus healthy controls, outperforming both CA125 and HE4 [160]. A plasma circRNA microarray profiling study further identified a two‐circRNA diagnostic model (circCOMBO: hsa_circ_0003972 and hsa_circ_0007288) with an AUC of 0.781, and when combined with CA125, the AUC improved to 0.923 [161]. A unique advantage of circRNA liquid biopsy in OC lies in the utilization of ascites fluid, which contains a high concentration of tumor‐derived molecules. A systematic review of RNA biomarkers in biofluids for early OC diagnosis highlighted ascites as a promising source for extracellular RNA‐based signatures, with multiple studies exploring the transcriptome of ascites from OC patients [157]. Despite their promising potential, challenges and opportunities remain for circRNA‐based liquid biopsy in OC. First, the sensitivity and specificity of circRNA detection methods require further refinement, particularly for low‐abundance circRNAs in peripheral blood [162]. Second, the mechanistic roles and biological functions of most dysregulated circRNAs in OC remain incompletely understood [163]. Additionally, translating circRNA research into clinical practice faces OC‐specific challenges: the high heterogeneity of ascites fluid across patients complicates standardized extraction protocols, and there is a lack of large‐scale prospective validation studies specifically in EOC populations [157]. Exosomes are nanoscale extracellular vesicles secreted by various cell types, with diameters typically ranging from 30 to 150 nm. They are present in diverse bodily fluids, including blood, urine, and ascites [164, 165], and carry bioactive molecules such as proteins, nucleic acids (e.g., miRNAs and long noncoding RNAs), and lipids. Exosomes mediate intercellular communication and participate in numerous physiological and pathological processes [164, 166]. Due to their high stability, low immunogenicity, minimal cytotoxicity, strong tissue penetration potential, and homing capability, exosomes are recognized as effective carriers for immunotherapeutic agents [164, 167]. Elevated expression levels of miR‐1290 and miR‐1307 in plasma‐derived exosomes have been identified as potential biomarkers and therapeutic targets for OC [165], offering utility in diagnosis, treatment, and prognosis evaluation [164]. Beyond these, a growing list of exosomal cargoes has been investigated in OC, including miRNAs such as miR‐21, miR‐200b, and miR‐205 [168], as well as proteins like EpCAM and CD24 [169]. Accumulating evidence indicates that miR‐1290 functions as an oncogenic miRNA in OC: it is significantly upregulated in OC tissues, cell lines and patient serum exosomes, and its high diagnostic accuracy (AUC = 0.794) may reflect its role in OC progression, suggesting its potential as a prognostic indicator [170, 171]. Mechanistically, miR‐1290 has been shown to promote OC cell proliferation and invasion, with studies reporting its targeting of OGN in cancer‐associated fibroblasts, leading to activation of the mTOR/Akt pathway [172]. Furthermore, miR‐1290 can inhibit SOCS4 expression in OC [170]. Since SOCS family proteins negatively regulate JAK/STAT signaling, the suppression of SOCS4 may lead to the activation of the JAK/STAT3 pathway [173]. These findings suggest that miR‐1290 may play a critical role in cancer progression and could serve as a diagnostic marker or therapeutic target. Despite their promise, the clinical application of exosomes in OC faces several challenges: First, the translation of exosome‐based concepts into clinical practice remains unrealized [164]. Second, the precise mechanisms and functional roles of exosomes require further investigation and validation. Third, the stability and detectability of exosomes across different biofluids need optimization to enhance reproducibility [165]. Clinical Translation and Screening Deployment Framework To date, there is no established gold standard for OC screening, and the field remains fraught with controversies. Therefore, the clinical translation of liquid biopsy technologies for OC requires the construction of a structured screening system centered on risk stratification. High‐risk populations include carriers of BRCA1/2 mutations, individuals with a first‐degree relative diagnosed with OC, and carriers of other pathogenic mutations such as those underlying Lynch syndrome. Specifically, the cumulative lifetime risk of OC reaches up to 39%–45% for BRCA1 mutation carriers [174], 11%–16% for BRCA2 mutation carriers [175], 2%–7.5% for individuals with one affected first‐degree relative [176], and 8% for carriers of other mutations including Lynch syndrome [177]. Although the efficacy of screening in this high‐risk cohort is still under investigation, combined screening with protease activity assays plus ctDNA testing is recommended every 6 months. For the general population without high‐risk factors, the cumulative lifetime risk of OC is ≤ 2% [177]. Most international guidelines, including those from China and the National Comprehensive Cancer Network (NCCN), do not recommend routine screening [178]. Instead, annual exploratory assessment with serum CA‐125 combined with transvaginal sonography (TVS) is suggested, while ctDNA or protease activity assays are not recommended for routine application in this population. For high‐risk populations, the pre‐test probability is set at ≥ 5%, indicating that prior to biomarker‐based testing, the estimated likelihood of developing OC in this group is 5% or higher. The positive threshold for ctDNA is defined as a variant allele frequency (VAF) of TP53 mutations ≥ 0.05% [72]; for protease activity, the cutoff value is set at matrix metalloproteinase 3 (MMP3) activity ≥ 1.2 times the mean level in healthy individuals [148]. A positive screening result is determined if either of the two combined assays meets the respective threshold. For the general population, the pre‐test probability is set at ≤ 1.5%, reflecting a relatively low baseline cancer risk. The classic cutoff value of serum CA‐125 (35 U/mL) is retained [179], combined with TVS‐detected imaging abnormalities (ovarian mass with a diameter ≥ 2 cm accompanied by solid components) [180] as the positive criteria, to minimize unnecessary interventions arising from false‐positive results. Notable disparities exist in the cost and turnaround time across different detection modalities. Serum CA‐125 testing costs $50–80 per assay [181] with a turnaround time of 1–2 working days, making it suitable for initial screening of the average‐risk population. Targeted ctDNA sequencing costs approximately $1500–3000 per test and requires 7–10 working days for results [182], which is indicated for screening high‐risk populations and monitoring tumor recurrence. Protease activity assays using the G‐NBSs platform typically cost $800–1200 per test, with a turnaround time of 3–5 working days, but require fresh sample processing within 4 h [148], rendering it appropriate for combined screening in high‐risk groups. TVS costs $200–300 per examination and can be performed on‐site, serving as an imaging adjunct for all populations. Combined testing with multiple modalities costs $2500–4500 per session and is reserved exclusively for precision screening of high‐risk populations. As an emerging optical biosensing technology, the G‐NBSs protease activity assay platform has demonstrated potential for early OC screening in research settings. However, it has not yet obtained regulatory approval from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). To address regulatory hurdles, multi‐center consistency validation and standardization of fresh sample processing protocols (within 4 h) are imperative. Although ctDNA testing has been approved as a companion diagnostic, its current clinical application is primarily restricted to guiding targeted therapies (e.g., EGFR mutation‐directed treatments). For early OC screening, additional clinical validation data focusing on core target mutations (e.g., BRCA1/2 alterations) are urgently needed [32]. Both technologies face challenges including high costs (not covered by medical insurance) and insufficient ethnicity‐specific data, particularly for Asian populations, who account for approximately 51.8% of the global OC burden [183]. At present, these modalities remain in the clinical validation phase, and large‐scale multi‐center studies are required to accelerate their clinical translation. Common Methodological Pitfalls and Mitigation Strategies Despite the remarkable clinical potential of liquid biopsy technologies in the early diagnosis, therapeutic response monitoring, and recurrence surveillance of OC, the field is plagued by several unresolved methodological challenges that may compromise the accuracy and reliability of technology translation. At the study design level, small sample sizes (mostly < 100 cases [69], spectrum bias caused by over‐enrollment of advanced‐stage patients [184, 185]), and the lack of long‐term follow‐up in retrospective studies tend to overestimate the diagnostic performance of assays and hinder the validation of their long‐term predictive value [69]. During analytical validation, most diagnostic models have not undergone external independent cohort validation [186], and some studies suffer from statistical over‐optimism due to uncorrected multiple comparisons, resulting in poor generalizability. In sample preprocessing, the confounding effects of blood collection tube types, transportation temperatures, processing timeframes, and patient comorbidities (e.g., infections and inflammation, which can elevate circulating free DNA levels) [186] are often overlooked. Furthermore, existing cohorts limited data from asymptomatic high‐risk individuals and the general population. To promote the standardized development and clinical translation of OC liquid biopsy technologies, future research should focus on the following directions: ① Adopt prospective cohort designs with expanded sample sizes (≥ 1000 cases), covering populations across different risk strata, and extend follow‐up duration to ≥ 5 years to fully capture long‐term clinical outcomes; ② Strengthen the analytical validation system, requiring all diagnostic models to be validated in at least one external independent cohort, with clear reporting of blinded study design and biomarker threshold setting methods; ③ Standardize sample preprocessing protocols, unify operating specifications for blood collection, transportation, and processing, and provide detailed disclosures in study reports; ④ Conduct head‐to‐head benchmarking studies to systematically compare the diagnostic efficacy and long‐term cost‐effectiveness of different liquid biopsy technologies against conventional detection methods; ⑤ Evaluate model stability using methods such as cross‐validation and Bootstrap resampling, and strictly control Type I errors in multiple comparisons to avoid statistical over‐optimism; ⑥ Enhance the representativeness of study cohorts by including individuals of diverse ethnicities, ages, and comorbidity profiles to improve the clinical applicability of research findings. Conclusion This review makes three novel contributions: first, it innovatively incorporates the protease activity‐based platform as a functional complement into the liquid biopsy system for OC and systematically compares its application scenarios with those of ctDNA and CTCs; second, it constructs a risk stratification‐oriented clinical translation framework, defining screening strategies, thresholds, and implementation challenges for distinct risk populations; third, by focusing on OC subtype‐specific features (e.g., the high TP53 mutation rate in high‐grade serous carcinoma), it provides targeted evidence that overcomes the limitations of pan‐cancer reviews. Liquid biopsy technologies have achieved important milestones in oncology, such as the FDA approval of companion diagnostic assays, which has accelerated clinical implementation, particularly in lung cancer. In OC, ctDNA profiling recapitulates tissue‐based molecular landscapes and has demonstrated prognostic value, while CTCs enable phenotypic and functional analyses despite persistent technical challenges that drive the development of novel capture platforms. The protease activity‐based approach, as a functional dimension, shows potential superiority over static markers in early detection and recurrence surveillance. In summary, the integration of genotypic, phenotypic, and functional liquid biopsy modalities can comprehensively reveal tumor biology and strengthen precision medicine for OC. Multimodal integration represents the core direction of future development. However, the full clinical potential of these biomarkers will only be realized through continued rigorous validation in large‐scale, OC‐specific prospective studies. Author Contributions Jingxia Zhang: methodology, writing – original draft. Qiaoping Xu: project administration. Weiyan Shan: software. Jie Yu: visualization. Huan Shi: data curation. Hongkai Shang: writing – review and editing. Funding This study was funded by the National Natural Science Foundation of China (grant no. 82171659); the Construction Fund for Key Medical Disciplines of Hangzhou (grant no. 2025HZZD07); the Zhejiang Provincial Medical and Health Science and Technology Program (grant no. 2023KY933); the Zhejiang Province Traditional Chinese Medicine Science and Technology Project (grant nos. 2023ZL565, 2022ZA139); and the Zhejiang Provincial Natural Science Foundation of China (grant no. LY21H040001). Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.